Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, ganciclovir sodium (Cymevene®) cannot be endorsed for use within NHS Wales from birth until 12 years for the prevention of cytomegalovirus disease using universal prophylaxis in patients with drug-induced immunosuppression (for example following organ transplantation or cancer chemotherapy). |
||
|
||
Medicine details |
||
| Medicine name | ganciclovir sodium (Cymevene®) | |
| Formulation | 500 mg powder for concentrate for solution for infusion | |
| Reference number | 3861 | |
| Indication | From birth until 12 years for the prevention of cytomegalovirus disease using universal prophylaxis in patients with drug-induced immunosuppression (for example following organ transplantation or cancer chemotherapy). |
|
| Company | Roche Products Ltd | |
| BNF chapter | Infections | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 23/07/2018 | |